ctDNA在上皮性卵巢癌的應用

Application of ctDNA in epithelial ovarian cancer

CA-125是上皮性卵巢癌中最為常見也最為熟悉的biomarker生物標記，然而目前為止，其特異性及敏感性仍然不足以被建議納入卵巢癌的篩檢當中。隨著科技不斷進步，目前有一種非侵入性的生物標記，為循環腫瘤DNA（ctDNA），目前有多方研究針對其在疾病的早期診斷、預後、監測等方面做探討。一些研究顯示，在卵巢癌患者中，ctDNA的檢測可用於早期診斷，並且在治療過程中可以追蹤疾病的進展，還可用於監測治療反應並預測其預後，然而ctDNA的臨床應用還需要更多更詳細的研究，以建立更明確的結論。

CA-125 is the most common and familiar biomarker in epithelial ovarian cancer; however, its specificity and sensitivity are currently insufficient to recommend it for inclusion in ovarian cancer screening program. With advancing technology, there is now a non-invasive biomarker known as circulating tumor DNA (ctDNA). Multiple studies are currently investigating its role in early disease diagnosis, prognosis, and monitoring. Some studies indicated that in ovarian cancer patients, ctDNA detection can be used for early diagnosis, tracking disease progression during treatment, monitoring treatment response, and predicting prognosis. However, further and more detailed research is still needed to establish more definitive conclusions regarding the clinical application of ctDNA.